Ulrich Granzer

Dr. Ulrich Granzer is a prominent figure in the field of regulatory affairs and drug development. He is the Owner and CEO of Granzer Regulatory Consulting & Services, a consultancy that specializes in providing strategic and operational support for drug and device development, as well as regulatory affairs. His firm has been operational since 2002 and has advised over 500 life science companies globally, focusing particularly on novel and orphan drugs.12

Educational Background and Career

Dr. Granzer holds a PhD in Pharmacology from the University of Tübingen in Germany. He began his career at GlaxoWellcome and has held significant positions in regulatory affairs at major pharmaceutical companies, including BASF Pharma and Bayer AG, where he had global responsibilities.12 In 2004, he joined Wellington Partners as a Venture Partner, contributing his expertise to the Life Science team.1

Contributions and Expertise

With a track record of working on more than 300 new molecular entities, Dr. Granzer is well-versed in navigating the complexities of regulatory requirements across various jurisdictions, including the US and Europe. His consultancy assists clients from the initial contact with regulatory authorities through to dossier preparation and submission processes.34

Professional Network

Dr. Granzer is active on LinkedIn, where he connects with professionals in the life sciences sector, showcasing his extensive network and contributions to discussions on drug research and development.4

In summary, Dr. Ulrich Granzer is a highly respected consultant with deep knowledge in regulatory affairs, making significant contributions to the pharmaceutical industry through his consultancy services.